Spyre Therapeutics, Inc.

SYRE • Biotechnology

$91.75

▲ +0.35 (+0.38%)

Precio actual

ResultadosÚltimo reporte: 30 jun 2026

PERFIL DÉBILDébilConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Perfil histórico débil. La evidencia actual no sostiene una relación riesgo/retorno favorable.

Capitalización

$7.67B

Crecimiento

—

Flujo de caja

0/5

Tendencia

Negative

Evidencia

Nivel de deuda manejable · 0Liquidez saludable · 13.25Tendencia de crecimiento negativaRentabilidad débil

Datos financieros hasta: 30 jun 2026, 12:00 a.m. UTCÚltima actualización de earnings: 30 jun 2026, 12:00 a.m. UTCÚltima actualización del perfil: 6 ago 2026, 12:35 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$91.75

Change0.38%

Shares Out84.73M

Market Cap$7.67B

Enterprise Value$6.52B

52W Range14.51 - 108.14

Beta3.02

P/E-42.86

P/S84.74

P/B6.96

P/FCF-36.67

EV/Sales72.08

Price$91.75

Change0.38%

Shares Out84.73M

Market Cap$7.67B

Enterprise Value$6.52B

52W Range14.51 - 108.14

Beta3.02

P/E-42.86

P/S84.74

P/B6.96

P/FCF-36.67

EV/Sales72.08

EV/EBITDA-35.15

EV/FCF-31.19

Earnings Yield-2.33%

FCF Yield-2.73%

Dividend Yield0.00%

Gross Margin0.00%

Oper. Margin0.00%

Profit Margin0.00%

Debt/Eq0.00

Current Ratio13.25

Quick Ratio13.25

Target$119.89

Target Upside30.67%

Target Median$120.00

Target Range107.00 - 130.00

Volume1.04M

Avg Volume1.32M

EPS Surprise-0.08

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

22/100

Fortaleza financiera

Deuda, caja, estabilidad

70/100

Potencial de crecimiento

Ingresos y expansión

20/100

Atractivo del precio

Barata o cara hoy

20/100

Por qué este puntaje▼

Nivel de deuda manejable · 0Liquidez saludable · 13.25Tendencia de crecimiento negativaRentabilidad débil

Analyst view

Analyst sentiment and price target

SYRE

Analyst sentiment

Based on 13 analyst votes · 2026-10-20

96/100

Bullish

Hold

Bearish

Precio objetivo

2026-08-06

Bajo

$49.00

Promedio

$105.36

Mediana

$112.00

Alto

$135.00

Resumen de la compañía

IPO: 4/7/2016

Industria: Biotechnology

P/B i: 6.96

Deuda / Patrimonio i: 0.00

Margen operativo: 0.00%

Margen neto: 0.00%

ROE i: -

ROIC: -

Salud financiera

Puntaje14 / 20

Deuda / Patrimonio: 0.00

Ratio corriente: 13.25

Ratio rápido: 13.25

Estado: Good

Transacciones internas

Actividad reciente de ejecutivos e insiders

⚠ 1 venta interna de alto volumen detectada

Turtle Cameron

Transacción: 08/03/2026

VENTA

Cambio

-16

Precio

$97.46

Presentación

08/05/2026

Tipo

VENTA

Burrows Scott L

Transacción: 08/03/2026

VENTA

Cambio

-100

Precio

$97.10

Presentación

08/05/2026

Tipo

VENTA

Burrows Scott L

Transacción: 08/03/2026

VENTA

Cambio

-7,500

Precio

$14.50

Presentación

08/05/2026

Tipo

VENTA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
Turtle Cameron	VENTA	-16	$97.46	08/03/2026	08/05/2026
Burrows Scott L	VENTA	-100	$97.10	08/03/2026	08/05/2026
Burrows Scott L	VENTA	-7,500	$14.50	08/03/2026	08/05/2026
Turtle Cameron	VENTA	-590	$88.91	07/01/2026	07/02/2026
Sloan Sheldon	VENTA	-1,834	$88.34	07/01/2026	07/02/2026
Sloan Sheldon	VENTA	-8,334	$27.46	07/01/2026	07/02/2026
Burrows Scott L	VENTA	-1,725	$88.37	07/01/2026	07/02/2026
Burrows Scott L	VENTA	-7,500	$14.50	07/01/2026	07/02/2026
Burrows Scott L	VENTA	-10,000	$87.14	06/25/2026	06/26/2026
Burrows Scott L	VENTA	-15,000	$14.50	06/25/2026	06/26/2026
Fairmount Funds Management LLC	VENTA	-16,667	Not reported	06/23/2026	06/23/2026
Fairmount Funds Management LLC	VENTA	-4,684,781	$85.31	06/23/2026	06/23/2026
HENDERSON MICHAEL THOMAS	VENTA	-20,000	$100.00	06/22/2026	06/23/2026
Sloan Sheldon	VENTA	-8,333	$75.00	06/03/2026	06/03/2026
Sloan Sheldon	VENTA	-8,333	$27.46	06/03/2026	06/03/2026
Burrows Scott L	VENTA	-3,100	$72.06	06/01/2026	06/03/2026
Burrows Scott L	VENTA	-7,500	$14.50	06/01/2026	06/03/2026
Turtle Cameron	VENTA	-3,294	$71.38	06/01/2026	06/03/2026
Milligan Sandra	COMPRA	+8,026	$72.51	05/27/2026	05/29/2026
McKenna Mark C.	COMPRA	+8,026	$72.51	05/27/2026	05/29/2026

Sobre la compañía

Spyre Therapeutics, Inc.

Spyre Therapeutics, Inc. is a biotechnology firm operating at the preclinical stage, dedicated to creating innovative treatments for individuals afflicted with inflammatory bowel disease (IBD). Among its pipeline candidates is SPY001, a human monoclonal immunoglobulin G1 antibody specifically engineered to target and bind with the a4ß7 integrin. This particular therapy is under development for addressing both ulcerative colitis and Crohn's disease, two forms of IBD. Furthermore, Spyre Therapeutics is advancing SPY002, another human monoclonal antibody that aims to interact with tumor necrosis factor-like ligand 1A (TL1A). A synergistic approach is also being explored with SPY120, a compound that merges the anti-a4ß7 action of SPY001 with the anti-TL1A activity of SPY002. All these programs are currently undergoing preclinical evaluation. Beyond these, the company's early-stage portfolio encompasses several additional promising candidates: SPY003, an anti-IL-23 monoclonal antibody; SPY004, a monoclonal antibody with a novel mechanism of action; SPY130, which combines anti-a4ß7 and anti-IL-23 antibodies; and SPY230, a dual antibody therapy featuring anti-TL1A and anti-IL-23 components. Originally incorporated in 2013, the organization was previously known as Aeglea BioTherapeutics, Inc., before rebranding to Spyre Therapeutics, Inc. in November 2023. Its headquarters are located in Waltham, Massachusetts.

Fuente - Link

Competidores

ABCL ARDX CLDX IMNM MAZE NTLA PHVS UPB WVE ZYME

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026

WALTHAM, Mass., Oct. 18, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced presentations at United European Gastroenterology Week (UEGW) 2026 in Barcelona. The presentations include the first scientific congress presentation of clinical data across all three of Spyre's IBD antibodies—SPY001 (anti-α4β7), SPY002 (anti-TL1A), and SPY003 (anti-IL-23)—which are now being tested as monotherapies and pairwise combinations in the SKYLINE study, as well as new preclinical data demonstrating additive efficacy of these complementary mechanisms.

GlobeNewsWire

Spyre: Maintain 'Strong Buy' On Additional SPY072 Shots On Goal Q4 2026 And IBD Combination Potential

Spyre Therapeutics maintains a 'Strong Buy' rating, driven by promising IBD pipeline progress and robust cash reserves. SYRE's three monotherapy candidates—SPY001, SPY002, SPY003—show potential best-in-class efficacy for IBD, with combination data expected in 2027. Despite discontinuing SPY072 monotherapy for RA, SYRE retains upside via upcoming PsA, axSpA, and combination readouts in late 2026–2028.

Seeking Alpha

Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock

WALTHAM, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced the pricing of its previously announced underwritten public offering of 4,117,648 shares of its common stock at a price to the public of $85.00 per share. The gross proceeds to the Company from this offering are expected to be approximately $350.0 million, before deducting underwriting discounts and commissions and other offering expenses. In addition, the Company has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional approximately $52.5 million of shares of the Company's common stock offered in the public offering under the same terms and conditions. The offering is expected to close on or about October 7, 2026, subject to satisfaction of customary closing conditions.

GlobeNewsWire

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock

WALTHAM, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that it has commenced an underwritten public offering of its common stock. In addition, the Company is expected to grant the underwriters of the offering an option for a period of 30 days to purchase an additional 15% of the shares of common stock offered in the public offering under the same terms and conditions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

GlobeNewsWire

Spyre (NASDAQ: SYRE) legal chief trims stake in planned share sale

What happened Spyre Therapeutics, Inc. (NASDAQ: SYRE) Chief Legal Officer and Corporate Secretary Heidy King-Jones sold 28,933 shares on 2026-10-01. The Form 4 shows five sale blocks at weighted-average prices from $89.24 to $93.46 per share, totaling about $2.63 million. It also shows a separate 28,933-share option exercise at $14.5 per share, and the filing

Defense World

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-05	-0.66	-0.74	-0.08
2026-02-19	-0.66	-0.7	-0.04
2025-11-04	-0.68	-0.15	0.53
2025-08-05	-0.73	-0.49	0.24
2025-05-08	-0.76	-0.74	0.02
2025-02-27	-0.89	-0.81	0.08
2024-11-07	-0.8	-1.36	-0.56
2024-08-07	-0.9	-0.86	0.04
2024-05-09	-0.9	-1.2	-0.3
2024-02-29	-0.48	-2.28	-1.8
2023-11-09	-0.84	-9.34	-8.5
2023-08-11	-4.5	-1.66	2.84